CoChat

New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota

Open access
Lorente-Picón, Marina, Laguna, Ariadna · 2021 · Biomolecules

The DOI matches its Crossref record; 365 of the 366 references it cites were found in a registry or an index.

Abstract

Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom11030433

Cites

365 of 365 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Disease-modifying strategies based on the gut microbiota. (1) The gut microbiota composition is influenced by several intrinsic (i.e., genetics, aging and immune system function) and extrinsic factors, including dietary habits (e.g., Mediterranean diet vs. Western diet) and environmental conditions (e.g., healthy environment vs pesticides/polluted environment). (2) Several strategies can be used to modify the composition of the gut microbiota to revert a dysbiotic condition: antibiotics, probiotics, fecal microbiota transplants (FMT), live biotherapeutic products (LBP), and dietary factors. (3) As a result, the balance between healthy/harmful bacteria, the presence of dietary fibers, the levels of metabolites with anti/pro-oxidant and anti/pro-inflammatory properties (e.g., omega-3 fatty acids, polyphenols, short chain fatty acids (SCFA), saturated fatty acids), and the aggregation of proteins like α-synuclein in the gut will be modified. (4) Because of the existing communication between the gut and the brain, these changes in the gut may have a direct impact on brain function through different mechanisms: levels of neurotransmitters, cytokines, reactive oxygen species (ROS), neurotrophic factors, and aggregation of α-synuclein. Overall, changes of the gut microbiota composition can have a beneficial or detrimental impact on the neurodegenerative process occurring in Parkinson’s disease.
Figure 1 Disease-modifying strategies based on the gut microbiota. (1) The gut microbiota composition is influenced by several intrinsic (i.e., genetics, aging and immune system function) and extrinsic factors, including dietary habits (e.g., Mediterranean diet vs. Western diet) and environmental conditions (e.g., healthy environment vs pesticides/polluted environment). (2) Several strategies can be used to modify the composition of the gut microbiota to revert a dysbiotic condition: antibiotics, probiotics, fecal microbiota transplants (FMT), live biotherapeutic products (LBP), and dietary factors. (3) As a result, the balance between healthy/harmful bacteria, the presence of dietary fibers, the levels of metabolites with anti/pro-oxidant and anti/pro-inflammatory properties (e.g., omega-3 fatty acids, polyphenols, short chain fatty acids (SCFA), saturated fatty acids), and the aggregation of proteins like α-synuclein in the gut will be modified. (4) Because of the existing communication between the gut and the brain, these changes in the gut may have a direct impact on brain function through different mechanisms: levels of neurotransmitters, cytokines, reactive oxygen species (ROS), neurotrophic factors, and aggregation of α-synuclein. Overall, changes of the gut microbiota composition can have a beneficial or detrimental impact on the neurodegenerative process occurring in Parkinson’s disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Items 201–365 of 365

Cited by

See all 72

Metadata

Authors
Lorente-Picón, M., & Laguna, A.
Affiliations
  • Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
Corresponding author
Laguna, Ariadna
Venue
Biomolecules
Publisher
MDPI AG
Published
2021-03-15
Volume
11
Issue
3
Pages
433
ISSN
2218-273X (ISSN-L)
OpenAlex
W3139351167
Cited by
69
References
366
Citations by year
2026: 8 · 2025: 12 · 2024: 10 · 2023: 13 · 2022: 17 · 2021: 9
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
La Caixa Banking Foundation (LCF/BQ/PR19/11700005)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
Parkinson's disease, gut microbiota, gut-brain axis, disease-modifying therapy, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, live biotherapeutic products, antibiotics, dietary intervention, motor symptoms, neurodegeneration
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain, Humans, Parkinson Disease, Phylogeny, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.